BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease

STOCKHOLM, Oct. 2, 2018 -- (Healthcare Sales & Marketing Network) -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a Notice of Option Exercise under the Research, Development, Option and License Agreement dat... Biopharmaceuticals, Neurology, Licensing BioArctic, AbbVie, alpha-synuclein, Parkinson's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news